 Marco De Dominici
Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2023 | 286 | 1.480 |
Why?
| | Cyclin-Dependent Kinase 6 | 3 | 2021 | 41 | 1.350 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2022 | 33 | 0.740 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 3 | 2018 | 236 | 0.670 |
Why?
| | Skin | 2 | 2023 | 765 | 0.620 |
Why?
| | Skin Neoplasms | 2 | 2023 | 849 | 0.570 |
Why?
| | Neoplasms | 2 | 2026 | 2741 | 0.560 |
Why?
| | Hematopoietic Stem Cells | 4 | 2024 | 411 | 0.560 |
Why?
| | Recombinant Fusion Proteins | 1 | 2020 | 672 | 0.530 |
Why?
| | Protein Kinase Inhibitors | 3 | 2021 | 914 | 0.470 |
Why?
| | Aging | 1 | 2026 | 1893 | 0.460 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2363 | 0.450 |
Why?
| | Proto-Oncogene Proteins c-myb | 4 | 2021 | 10 | 0.430 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2018 | 125 | 0.390 |
Why?
| | Clone Cells | 2 | 2023 | 266 | 0.360 |
Why?
| | Gene Expression Regulation, Leukemic | 3 | 2021 | 55 | 0.330 |
Why?
| | STAT5 Transcription Factor | 2 | 2018 | 57 | 0.260 |
Why?
| | Cell Proliferation | 5 | 2025 | 2504 | 0.230 |
Why?
| | Orthomyxoviridae Infections | 1 | 2025 | 68 | 0.220 |
Why?
| | Tumor Suppressor Proteins | 2 | 2018 | 325 | 0.220 |
Why?
| | Stem Cell Niche | 1 | 2024 | 58 | 0.210 |
Why?
| | Fusion Proteins, bcr-abl | 4 | 2021 | 70 | 0.200 |
Why?
| | Mice | 12 | 2025 | 18055 | 0.200 |
Why?
| | Antineoplastic Agents | 3 | 2021 | 2166 | 0.190 |
Why?
| | DNA Modification Methylases | 1 | 2022 | 17 | 0.190 |
Why?
| | MicroRNAs | 2 | 2018 | 689 | 0.180 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 899 | 0.180 |
Why?
| | Lymphoma, B-Cell | 1 | 2023 | 130 | 0.180 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 37 | 0.180 |
Why?
| | Molecular Targeted Therapy | 2 | 2021 | 420 | 0.170 |
Why?
| | Genes, cdc | 1 | 2020 | 11 | 0.160 |
Why?
| | Chromatin | 2 | 2021 | 529 | 0.160 |
Why?
| | Apoptosis | 5 | 2020 | 2574 | 0.150 |
Why?
| | Animals | 13 | 2025 | 37663 | 0.150 |
Why?
| | Cell Line, Tumor | 4 | 2020 | 3470 | 0.150 |
Why?
| | Interleukin-1beta | 1 | 2021 | 380 | 0.150 |
Why?
| | Humans | 19 | 2026 | 141197 | 0.150 |
Why?
| | Molecular Structure | 1 | 2020 | 503 | 0.150 |
Why?
| | Blast Crisis | 1 | 2018 | 33 | 0.150 |
Why?
| | Enzyme Activation | 1 | 2020 | 811 | 0.140 |
Why?
| | RNA, Neoplasm | 1 | 2018 | 79 | 0.140 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2016 | 53 | 0.140 |
Why?
| | Phosphorylation | 2 | 2020 | 1768 | 0.140 |
Why?
| | Multigene Family | 1 | 2018 | 202 | 0.140 |
Why?
| | Gene Silencing | 1 | 2018 | 196 | 0.130 |
Why?
| | Cell Cycle | 1 | 2020 | 597 | 0.130 |
Why?
| | Celecoxib | 1 | 2016 | 39 | 0.130 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2017 | 63 | 0.130 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2016 | 62 | 0.130 |
Why?
| | Transcriptional Activation | 1 | 2018 | 378 | 0.120 |
Why?
| | Histones | 1 | 2021 | 639 | 0.120 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 129 | 0.120 |
Why?
| | Hematopoiesis | 1 | 2017 | 194 | 0.120 |
Why?
| | Mutation | 3 | 2024 | 4013 | 0.120 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2015 | 19 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1764 | 0.120 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2016 | 199 | 0.110 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2021 | 646 | 0.110 |
Why?
| | Nerve Tissue Proteins | 1 | 2018 | 601 | 0.110 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2015 | 193 | 0.110 |
Why?
| | beta Catenin | 1 | 2016 | 258 | 0.110 |
Why?
| | Cells, Cultured | 1 | 2022 | 4208 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2021 | 2003 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2025 | 2250 | 0.100 |
Why?
| | Proto-Oncogene Proteins | 2 | 2017 | 623 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2018 | 1155 | 0.090 |
Why?
| | Lung | 1 | 2025 | 4134 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2025 | 2560 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4405 | 0.090 |
Why?
| | Leukemia, B-Cell | 1 | 2011 | 13 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2011 | 20 | 0.090 |
Why?
| | Melanoma | 1 | 2018 | 772 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2011 | 333 | 0.080 |
Why?
| | Repressor Proteins | 1 | 2011 | 425 | 0.070 |
Why?
| | K562 Cells | 2 | 2018 | 95 | 0.070 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 1048 | 0.070 |
Why?
| | Cell Lineage | 2 | 2021 | 350 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2018 | 830 | 0.070 |
Why?
| | Nuclear Proteins | 1 | 2011 | 712 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2020 | 11120 | 0.060 |
Why?
| | Cell Survival | 2 | 2018 | 1129 | 0.050 |
Why?
| | Gene Expression | 2 | 2021 | 1491 | 0.050 |
Why?
| | Cell Line | 2 | 2021 | 2885 | 0.050 |
Why?
| | Bone Marrow | 1 | 2024 | 302 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2025 | 674 | 0.050 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 2021 | 7 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2025 | 1150 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2025 | 792 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1787 | 0.040 |
Why?
| | Disease Progression | 2 | 2018 | 2793 | 0.040 |
Why?
| | Dexamethasone | 1 | 2023 | 380 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2021 | 151 | 0.040 |
Why?
| | Pyridines | 1 | 2023 | 510 | 0.040 |
Why?
| | Signal Transduction | 3 | 2018 | 5144 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2025 | 918 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2025 | 1110 | 0.040 |
Why?
| | Philadelphia Chromosome | 1 | 2018 | 18 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 737 | 0.040 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2018 | 40 | 0.040 |
Why?
| | Semaphorins | 1 | 2018 | 35 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2018 | 250 | 0.030 |
Why?
| | Mice, SCID | 1 | 2018 | 369 | 0.030 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2017 | 15 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2017 | 18 | 0.030 |
Why?
| | Antigens, CD34 | 1 | 2017 | 89 | 0.030 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2016 | 22 | 0.030 |
Why?
| | Mice, Nude | 1 | 2018 | 691 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2016 | 80 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2016 | 73 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 601 | 0.030 |
Why?
| | Transfection | 1 | 2018 | 943 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 97 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 5887 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2018 | 626 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 74 | 0.030 |
Why?
| | Drug Synergism | 1 | 2016 | 375 | 0.030 |
Why?
| | DNA Replication | 1 | 2017 | 240 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 668 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2015 | 82 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 640 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2015 | 147 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 196 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2016 | 959 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 2016 | 176 | 0.030 |
Why?
| | Trans-Activators | 1 | 2017 | 388 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2015 | 274 | 0.030 |
Why?
| | Small Molecule Libraries | 1 | 2015 | 98 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2015 | 194 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2015 | 521 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2064 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2018 | 1073 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 2098 | 0.020 |
Why?
| | Models, Molecular | 1 | 2015 | 1603 | 0.020 |
Why?
| | Inflammation | 1 | 2021 | 2889 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4073 | 0.020 |
Why?
| | Databases, Factual | 1 | 2015 | 1444 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2599 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 6956 | 0.010 |
Why?
| | Female | 2 | 2025 | 75522 | 0.010 |
Why?
| | Adult | 1 | 2023 | 39181 | 0.010 |
Why?
| | Male | 1 | 2015 | 69789 | 0.000 |
Why?
|
|
De Dominici's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|